This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
As a condition of publication of phase III clinical trials, medical journals should insist on the release of all raw data and a written independent clinical audit.
Editorials and commentaries in some high-profile journals herald an upcoming revolution in personalised oncology. However, any new treatment can only be considered an advance if it.
Link to access the full article: https://www.ncbi.nlm.nih.gov/pubmed/22106997